Last reviewed · How we verify

Libtayo (CEMIPLIMAB)

Regeneron Pharmaceuticals · FDA-approved approved Monoclonal antibody Quality 64/100

Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.

Libtayo (cemiplimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, targeting the programmed cell death protein 1 (PD-1). It works by blocking the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. Libtayo is approved to treat various types of cancer, including cervical cancer, basal cell carcinoma, and non-small cell lung cancer. It remains a patented product, and its commercial status is unchanged. Key safety considerations include immune-mediated adverse reactions and potential liver damage.

At a glance

Generic nameCEMIPLIMAB
SponsorRegeneron Pharmaceuticals
TargetPD-1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2018
Annual revenue1452

Mechanism of action

Cemiplimab-rwlc works by binding to the PD-1 receptor on T cells, preventing it from interacting with its ligands PD-L1 and PD-L2. This blockage releases the inhibition of T-cell activity, allowing the immune system to better recognize and attack tumor cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: